Osteoporosis in otherwise healthy perimenopausal and early postmenopausal women: physical and biochemical characteristics.
Population studies have shown that about 3-5% of perimenopausal women already have osteoporosis according to the WHO definition of osteoporosis for postmenopausal women ( t -score<or=-2.5). In general, this bone loss arises from well-characterized diseases or conditions that affect acquisition of peak bone mass and/or the rate of bone loss after peak bone mass has been attained. However, there often remains a subset of these women, with no identifiable cause of bone loss. This group has so far been little studied. We prospectively evaluated a group of 60 perimenopausal and early postmenopausal women (mean age 52.2+/-2.5 years) who were found to have apparently unexplained low bone mass, and we compared them to 120 controls matched for age and menopausal status. These women were extensively investigated, including by detailed questionnaire and laboratory testing. Of the 60 women with osteoporosis, only three were found to have previously undiagnosed disorders (two with subclinical hyperthyroidism and one with elevated serum PTH levels) that might have contributed to their low bone mass. On the other hand, osteoporotic patients were characterized by a significantly lower body weight, higher prevalence of personal and parental histories of fractures and a higher level of bone turnover as assessed by increased serum osteocalcin and bone alkaline phosphatase levels and urinary type I collagen C-telopeptide (CTX) excretion, as compared to controls. These findings support theories of a genetic contribution to osteoporosis and underline the predictive value of a previous history of personal and familial fracture in the identification of osteoporosis in early postmenopausal women.
Pouillès
Jean-Michel
JM
Hôpital Paule de Viguier, Unité Ménopause et Maladies Osseuses et Métaboliques, 330 avenue de Grande Bretagne-TSA 70034-31059, Toulouse Cedex 9, France.
Trémollieres
Florence A
FA
Ribot
Claude
C
D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D015519:Bone Density / Q000502:physiology; D001862:Bone Resorption / Q000378:metabolism / Q000503:physiopathology; D024042:Collagen Type I / Q000652:urine; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000172:deficiency; D005260:Female; D005272:Femur Neck / Q000503:physiopathology; D050723:Fractures, Bone / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000503:physiopathology*; D010455:Peptides / Q000652:urine; D011446:Prospective Studies; D014808:Vitamin D Deficiency / Q000378:metabolism / Q000503:physiopathology
D015415:Biomarkers; D024042:Collagen Type I; D004967:Estrogens; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D004958:Estradiol; D000469:Alkaline Phosphatase